BTIG Maintains Buy on Glaukos, Raises Price Target to $205

10/12/2026
Impact: 70
Healthcare

BTIG analyst Ryan Zimmerman has maintained a Buy rating on Glaukos (NYSE: GKOS) and raised the price target from $202 to $205. This adjustment reflects confidence in the company's performance and future prospects.

AI summary, not financial advice

Share: